| 181 | 6 | 4 |
| 下载次数 | 被引频次 | 阅读次数 |
目的探究骨痿方对脾肾两虚兼血瘀型骨质疏松性椎体压缩性骨折(osteoporotic vertebral compression fractures,OVCF)患者术后骨代谢标志物的影响。方法选取2017年2月-2019年3月就诊于新疆医科大学第四附属医院脊柱二科的60例脾肾两虚兼血瘀型OVCF患者为研究对象,随机分为治疗组(30例)和对照组(30例),两组术后均给予常规抗骨质疏松治疗,治疗组在此基础上加服用骨痿方,治疗3个月后,分析比较两组患者服药前后骨吸收标志物β-CTX与骨形成标志物PINP、中医临床症状积分。结果与治疗前比较,两组患者治疗后β-CTX、PINP、中医临床症状积分均降低,差异有统计意义(P<0.05)。与对照组比较,治疗组β-CTX水平降低,中医临床症状积分降低,差异有统计意义(P<0.05), PINP水平降低,差异无统计意义(P>0.05)。结论脾肾两虚兼血淤型OVCF患者术后应采用骨痿方联合常规抗骨质疏松治疗,可有效改善骨代谢水平,减轻中医临床症状。
Abstract：Objective To explore the effect of Guwei decotion on bone metabolism markers in patients of osteoporotic vertebral compression fractures(OVCF) and complicated with spleen kidney deficiency and blood stasis. Methods From February 2017 to March 2019, 60 OVCF patients with spleen and kidney deficiency and blood stasis were selected as the research object, and randomly divided into the treatment group(30 cases) and the control group(30 cases). Both groups were given routine anti osteoporosis treatment after operation. On this basis, the treatment group was administerwith Guwei formula. Three months later, the bone absorption markers(β-CTX) and bone formation markers(PINP, TCM clinical symptom score) of both groups were analyzed and compared before and after treatment. Results Compared with before treatment, the scores of bone absorption markers(β-CTX), bone formation markers(PINP) and clinical symptoms of Traditional Chinese Medicine in both groups were decreased after treatment, the difference was statistically significant(P<0.05). Compared with the control group, the level of β-CTX in the treatment group was lower, the score of clinical symptoms in Traditional Chinese Medicine was lower, the difference was statistically significant(P<0.05), the level of PINP was lower, the difference was not statistically significant(P>0.05). Conclusion After operation, the patients with OVCF of spleen kidney deficiency and blood stasis type should be treated with Guwei formula combined with routine anti-osteoporosis treatment, which can effectively improve the level of bone metabolism and alleviate the clinical symptoms of Traditional Chinese Medicine.
[1] 中国中西医结合学会骨伤科专业委员会.骨质疏松症中西医结合诊疗指南[J].中华医学杂志,2019,99(45):3524-3533.
[2] WRIGHT N C,LOOKER A C,SAAG K G,et al.The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine[J].Bone Miner Research,2014,29(25):20-26.
[3] 张斌,程翔,李昌坤.经皮椎体成形术与非手术方式治疗中老年骨质疏松性椎体压缩骨折的疗效分析[J].川北医学院学报,2018,44(1):74-76.
[4] SABO A,HATGIS J,GRANVILLE M,et al.Multilevel contiguous osteoporotic lumbar compression fractures:the relationship of scoliosis to the development of cascading fractures [J].Cureus,2017,9(12):1962.
[5] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2017)[J].中华骨质疏松和骨矿盐疾病杂志,2017,20(5):413-443.
[6] 中华医学会骨科学分会骨质疏松学组.骨质疏松性骨折诊疗指南[J].中华骨科杂志,2017,37(1):1-10.
[7] 郑筱萸.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002,85.
[8] SEIBEL M J.Clinical application of biochemical markers of bone turnover[J].Arquivos Brasileiros de Endocrinologia Metabologia,2006,50(4):603-620.
[9] SHIGDEL R,OSIMA M,AHMED LA,et al.Bone turnover markers are associated with higher cortical porosity,thinner cortices,and larger size of the proximal femur and non-vertebral fractures[J].Bone,2015,31(6):1-6.
[10] MILLER P D,Bone density and markers of bone turnover in Predictingftacture risk and how changes in these measures predict fracture risk reduction[J].Curr Osteoporos Rep,2005,3(3):103-110.
[11] NAYLOR K E,JACQUES R M,PAGGIOSI M,et al.Response of boneturnover markers to three oral bisphosphonate therapies inpostmenopausal osteoporosis:the TRIO study[J].Osteoporosis International,2016,27(1):21-31.
[12] VASIKARAN S D,CHUBB S A.The use of biochemical markers of bone turnover in the clinical management of primary andsecondary osteoporosis[J].Endocrine,2016,52(2):222-225.
[13] 刘跃辉,张波,李伟,等.杜仲叶醇提取物对去卵巢骨质疏松大鼠骨代谢生化指标、骨密度、IL-6及TNF-α的影响[J].中医学报,2018,33(3):445-448.
[14] XIE F,WU C F,LAI W P,et al.The osteoprotective effect of Herba Epimedii ( HEP) extract in vivo and in vitro[J].Evidbased Compl Alt,2014,2(3):353-361.
[15] ZHAO X,WU Z X,ZHANG Y,et al.Anti-osteoporosis activity of Cibotium barometz extract on ovariectomy-induced bone loss in rats[J].Journal of Ethnopharmacology,2011,137(3):1083-1088.
[16] 史岩,马秋野,喻一东,等.骨碎补总黄酮促进骨质疏松性骨折愈合中参与Wnt /β-catenin信号通路的初步研究[J].中医药学报,2018,46(2):49-52.
[17] 韩亚力,罗奕,曾佳学.骨碎补总黄酮基于Notch信号通路改善骨质疏松的作用及机制研究[J].中国免疫学杂志,2018,2 (2):261-266.
[18] 柴艺汇,高洁,田兴中,等.黄芪多糖MC-3T3-E成骨细胞CYP27B,CYP24A mRNA及蛋白表达的影响[J].中国实验方剂学杂志,2018,24(13):167-171.
[19] NAKAMURA T.Effect and role of teriparatide in the treatment of osteoporosis[J].Clin Caldum,2012,22(3):310-314.
基本信息:
中图分类号:R274.1
引用信息:
[1]马玉梅,韩念荣,罗啸,等.骨痿方对脾肾两虚兼血瘀型OVCF患者术后骨代谢β-CTX、PINP影响的临床研究[J].新疆医科大学学报,2020,43(07):947-950.
基金信息:
新疆维吾尔自治区科技攻关计划(G161310012)
2020-07-15
2020-07-15